The backbone of the third filament system of the sarcomere is the huge titin molecule, spanning from the sarcomeric Z-disc to the M-line. Proteins in direct interaction and functionally integrated with titin, such as calpain 3 and telethonin, are part of the third filament system. The third filament system provides support to the contractile filament systems during development and mature states including mechanical properties and regulatory signaling functions. The first mutations in the third filament system causing human muscle disease were identified in calpain 3 in 1995, followed by telethonin and titin. In spite of some early ideas on what is going wrong in the muscle cells based on the defective proteins, the exact molecular pathomechanisms leading to muscle atrophy in patients with these disorders are still unknown. However, preparations for direct trials of gene therapy have already been launched, at least for calpainopathy.


Sarcomere Length Nonsense Mediate Decay Skeletal Muscle Disease Dilate Cardiomy Cardiac Titin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Labeit S, Gautel M, Lakey A et al. Towards a molecular understanding of titin. EMBO J 1992; 11:1711–1716.PubMedGoogle Scholar
  2. 2.
    Labeit S, Kolmerer B. Titins: Giant proteins in charge of muscle ultrastructure and elasticity. Science 1995; 270:293–296.PubMedCrossRefGoogle Scholar
  3. 3.
    Freiburg A, Gautel M. A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy. Eur J Biochem 1996; 235:317–323.PubMedCrossRefGoogle Scholar
  4. 4.
    Gautel M, Mues A, Young P. Control of sarcomeric, assembly: The flow of information on titin. Rev Physiol Biochem Pharmacol 1999; 38:97–137.CrossRefGoogle Scholar
  5. 5.
    Improta S, Politou AS, Pastore A. Immunoglobulin-like modules from titin I-band: Extensible components of muscle elasticity. Structure 1996; 4:323–337.PubMedCrossRefGoogle Scholar
  6. 6.
    Kolmerer B, Olivieri N, Witt CC et al. Genomic organization of M line titin and its tissue-specific expression in two distinct isoforms. J Mol Biol 1996; 256:556–563.PubMedCrossRefGoogle Scholar
  7. 7.
    Hoshijima M. Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin and associated structures. Am J Physiol Heart Circ Physiol 2006; 290(4):H1313–25.PubMedCrossRefGoogle Scholar
  8. 8.
    Witt SH, Labeit D, Granzier H et al. Dimerization of the cardiac ankyrin protein CARP: Implications for MARP titin-based signaling. J Muscle Res Cell Motil 2006; 1:1–8.Google Scholar
  9. 9.
    Lange S, Xiang F, Yakovenko A et al. The kinase domain of titin controls muscle gene expression and protein turnover. Science 2005; 308:1599–1603.PubMedCrossRefGoogle Scholar
  10. 10.
    Bang M-L, Centner T, Fornoff F et al. The complete gene sequence of titin, expression of an unusual 700-kDa titin isoform and its interaction with obscurin identify a novel Z-line to I-band linking system. Circ Res 2001; 89:1065–1072.PubMedCrossRefGoogle Scholar
  11. 11.
    Gautel M, Goulding D, Bullard B et al. The central Z-disk region of titin is assembled from a novel repeat in variable copy numbers. J Cell Sci 1996; 109:2747–2754.PubMedGoogle Scholar
  12. 12.
    Sorimachi H, Freiburg A, Kolmerer B et al. Tissue-specific expression and a-actinin binding properties of the Z-disc titin: Implications for the nature of vertebrate Z-discs. J Mol Biol 1997; 270:688–695.PubMedCrossRefGoogle Scholar
  13. 13.
    Trombitas K, Wu Y, Labeit S et al. Cardiac titin isoforms are expressed in the half-sarcomere and extend independently. Am J Physiol Heart Circ Physiol 2001; 285:H1793–1799.Google Scholar
  14. 14.
    Wu Y, Bell SP, Trombitas K et al. Changes in titin isoform expression in pacing-induced cardiac failure give rise to increased passive muscle stiffness. Circulation 2002; 106:1384–1389.PubMedCrossRefGoogle Scholar
  15. 15.
    Granzier H, Wu Y, Siegfried L et al. Titin: Physiological function and role in cardiomyopathy and failure. Heart Fail Rev 2005; 10(3):211–223.PubMedCrossRefGoogle Scholar
  16. 16.
    Lange S, Agarkova I, Perriard JC et al. The sarcomeric M-band during development and in disease. J Muscle Res Cell Motil 2006; 10:1–5.Google Scholar
  17. 17.
    Ojima K, Ono Y, Doi N et al. Myogenic state, sarcomere length and protease activity modulate localization of muscle-specific calpain. J Biochem 2007; E-publ.Google Scholar
  18. 18.
    Richard I, Broux O, Allamand V et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995; 81:27–40.PubMedCrossRefGoogle Scholar
  19. 19.
    Moreira ES, Wiltshire TJ, Faulkner G et al. Limb-girdle muscular dystrophy type 2G is caused by mutatiosn in the gene encoding the sarcomeric protein telethonin. Nat Genet 2000; 24(2):163–166.PubMedCrossRefGoogle Scholar
  20. 20.
    Gerull B, Gramlich M, Atherton J et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat Genet 2002; 30:201–204.PubMedCrossRefGoogle Scholar
  21. 21.
    Itoh-Satoh M, Hayashi T, Nishi H et al. Titin mutations as the molecular basis for dilated cardiomyopathy. Biochem Biophys Res Commun 2002; 291:385–393.PubMedCrossRefGoogle Scholar
  22. 22.
    Hackman P, Vihola A, Haravuori H et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am J Hum Genet 2002; 71:492–500.PubMedCrossRefGoogle Scholar
  23. 23.
    Carmignac V, Salih MA, Quijano-Roy S et al. C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. Ann Neurol 2007; 61(4):340–351.PubMedCrossRefGoogle Scholar
  24. 24.
    Satoh M, Takahashi M, Sakamoto T et al Structural analysis of the titin gene in hypertrophic cardiomyopathy: Identification of a novel disease gene. Bioch Biophys Res Commun 1999; 262:411–417.CrossRefGoogle Scholar
  25. 25.
    Seidman JG, Seidmann C. The genetics basis for cardiomyopathy: From mutation identification to manifestation paradigms. Cell 2001, 104:557–567.PubMedCrossRefGoogle Scholar
  26. 26.
    Gerull B, Atherton J, Geupel A et al. Identification of a novel frameshift mutation in the giant muscle filament titin in a large Australian family with dilated cardiomyopathy. J Mol Med 2006; 84(6):478–483.PubMedCrossRefGoogle Scholar
  27. 27.
    Matsumoto Y, Hayashi T, Inagaki N et al. Functional analysis of titin/connectin N2-B mutations found in cardiomyopathy. J Muscle Res Cell Motil 2006; 8:1–8.Google Scholar
  28. 28.
    Udd B, Kääriäinen H, Somer H: Muscular dystrophy with separate phenotypes in a large family. Muscle Nerve 1991; 14:1050–1058.PubMedCrossRefGoogle Scholar
  29. 29.
    Udd B, Partanen J, Halonen P et al. Tibial muscular dystrophy—Late adult onset distal myopathy in 66 Finnish patients. Arch Neurol 1993; 50:604–608.PubMedGoogle Scholar
  30. 30.
    Udd B, Vihola A, Sarparanta J et al. Titinopathies and extension of the M-line mutation phenotype beyond distal myopathy and LGMD2J. Neurology 2005; 64:636–642.PubMedGoogle Scholar
  31. 31.
    de Seze J et al. The first European tibial muscular dystrophy family outside the Finnish population. Neurology 1998;51:1746–1748.PubMedGoogle Scholar
  32. 32.
    Van den Bergh P, Bouquiaux O, Verellen C et al. Tibial muscular dystrophy in a Belgian family. Annal Neurol 2003; 54:248–251.PubMedCrossRefGoogle Scholar
  33. 33.
    Udd B et al. Imaging methods reveal unexpected patchy lesions in late onset distal myopathy. Neuromusc Disord 1991; 1:271–280.Google Scholar
  34. 34.
    Udd B et al. Nonvacuolar myopathy in a large family with both late adult onset distal myopathy and limb-girdle type muscular dystrophy. J Neurol Sci 1992; 113:214–221.PubMedCrossRefGoogle Scholar
  35. 35.
    Haravuori H et al. (1998). Assignment of the tibial muscular dystrophy (TMD) locus on chromosome 2q31. Am J Hum Genet 62:620–626.PubMedCrossRefGoogle Scholar
  36. 36.
    Udd B et al. Tibial muscular dystrophy—From clinical description to linkage on chromosome 2q31. Neuromusc Disord 1998; 8:327–332.PubMedCrossRefGoogle Scholar
  37. 37.
    Sorimachi H, Kinbara K, Kimura S et al. Muscle-specific Calpain, p94, responsible for limb girdle muscular dystrophy type 2A, associates with connectin through IS2, a p94-specific sequence. J Biol Chem 1995; 270:31158–31162.PubMedCrossRefGoogle Scholar
  38. 38.
    Haravuori H et al. Secondary calpain3 deficiency in 2q linked muscular dystrophy—Titin is the candidate gene. Neurology 2001; 56:869–877.PubMedGoogle Scholar
  39. 39.
    Houmeida A, Holt J, Tskhovrebova L et al. Studies of the interaction between titin and myosin. J Cell Biol 1995; 131:1471–1481.PubMedCrossRefGoogle Scholar
  40. 40.
    Meredith C, Herrmann R, Parry C et al. Mutations in the slow skeletal muscle fiber myosin heavy chain gene (MYH7) cause Laing early-onset distal myopathy (MPD1). Am J Hum Genet 2004; 75:703–708.PubMedCrossRefGoogle Scholar
  41. 41.
    Beatham J, Gehmlich K, van de Ven P et al. Constitutive upregulations in KY deficient muscles suggest early titin involvement in the mechanism of pathogenesis. Neuro musc Disord 2006; 16:437–445.CrossRefGoogle Scholar
  42. 42.
    Zastrow MS, Flaherty DB, Benian GM et al. Nuclear titin interacts with A-and B-type lamins in vitro and in vivo. J Cell Sci 2006; 119:239–49.PubMedCrossRefGoogle Scholar
  43. 43.
    Edstrom L, Thornell L, Albo J et al. Myopathy with respiratory failure and typical myofibrillar lesions. J Neurol Sci 1990; 96:211–128.PubMedCrossRefGoogle Scholar
  44. 44.
    Nicolao P, Xiang F Gunnarsson L et al. Autosomal dominant myopathy with proximal weakness and early respiratory muscle involvement maps to chromosome 2q. Am J Hum Genet 1999; 64:788–792.PubMedCrossRefGoogle Scholar
  45. 45.
    Xiang F, Nicolao P, Chapon F et al. A second locus for autosomal dominant myopathy with proximal muscle weakness and early respiratory muscle involvement: A likely chromosomal locus on 2q21. Neuromuscul Disord 1999; 9(5):308–312.PubMedCrossRefGoogle Scholar
  46. 46.
    Mayans O, van der Ven P, Wilm M et al. Structural basis for activation of the titin kinase domain during myofibrillogenesis. Nature 1998; 395:863–869.PubMedCrossRefGoogle Scholar
  47. 47.
    Amodeo P, Castiglione Morelli M, Strazzullo G et al. Kinase recognition by calmodulin: Modeling the interaction with the autoinhibitory region of human cardiac titin kinase. J Mol Biol 2001; 306:81–95.PubMedCrossRefGoogle Scholar
  48. 48.
    Gomes MD, Lecker SH, Jagoe RT et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci 2001; 98(25):14440–14445.PubMedCrossRefGoogle Scholar
  49. 49.
    Sotiropoulos A, Gineitis D, Copeland J et al. Signal-regulated activation of serum response factor is mediated by changes in actin dynamics. Cell 1999; 98:159–169.PubMedCrossRefGoogle Scholar
  50. 50.
    Sadoshima J and Izumo S. Mechanical stretch rapidly activates multiple signal transduction pathways in cardiac myocytes: Potential involvement of an autocrine/paracrine mechanism. EMBO J 1993; 12:1681–1692.PubMedGoogle Scholar
  51. 51.
    Carson J, Schwartz R, Booth F. SRF and TEF-1 control of chicken skeletal alpha-actin gene during slow-muscle hypertrophy. Am J Physiol 1996; 270:1624–1633.Google Scholar
  52. 52.
    Salih MA, Al Rayess M, Cutshall S et al. A novel form of familial congenital muscular dystrophy in two adolescents. Neuropediatrics 1998; 29:289–293.PubMedCrossRefGoogle Scholar
  53. 53.
    Taveau M, Bourg N, Sillon G et al. Calpain 3 is activated through autolysis within the active site and lyses sarcomeric and sarcolemmal components. Mol Cell Biol 2003; 23:9127–9135.PubMedCrossRefGoogle Scholar
  54. 54.
    Diaz BG, Moldoveanu T, Kuiper MJ et al. Insertion sequence 1 of muscle-specific calpain, p94, acts as an internal propeptide. J Biol Chem 2004; 279:27656–27666.PubMedCrossRefGoogle Scholar
  55. 55.
    Fanin M, Nascimbeni AC, Fulizio L et al. The frequency of limb girdle muscular dystrophy 2A in northeastern Italy. Neuromuscul Disord 2005; 15:218–224.PubMedCrossRefGoogle Scholar
  56. 56.
    Fardeau M, Eymard B, Mignard C et al. Chromosome 15-linked limb-girdle muscular dystrophy: Clinical phenotypes in Reunion Island and French metropolitan communities. Neuromuscul Disord 1996; 6:447–453.PubMedCrossRefGoogle Scholar
  57. 57.
    Anderson LV, Harrison RM, Pogue R et al. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord 2000; 10:553–559.PubMedCrossRefGoogle Scholar
  58. 58.
    Talim B, Ognibene A, Mattioli E et al. Normal calpain expression in genetically confirmed limb-girdle muscular dystrophy type 2A. Neurology 2001; 56:692–3.PubMedGoogle Scholar
  59. 59.
    Fanin M, Nascimbeni AC, Fulizio L et al. Loss of calpain-3 autocatalytic activity in LGMD2A patients with normal protein expression. Am J Pathol 2003; 163:1929–1936.PubMedGoogle Scholar
  60. 60.
    Jenne DE, Kley RA, Vorgerd M et al. Limb girdle muscular dystrophy in a sibling pair with a homozygous Ser606Leu mutation in the alternatively spliced IS2 region of calpain 3. Biol Chem 2005; 386:61–67.PubMedCrossRefGoogle Scholar
  61. 61.
    Lanzillo R, Aurino S, Fanin M et al. Early onset calpainopathy with normal non-functional calpain 3 level. Dev Med Child Neurol 2006; 48:304–306.PubMedCrossRefGoogle Scholar
  62. 62.
    Saenz A, Leturcq F, Cobo AM et al. LGMD2A: Genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain 2005; 128:732–742.PubMedCrossRefGoogle Scholar
  63. 63.
    Milic A, Daniele N, Lochmuller H et al. A third of LGMD2A biopsies have normal calpain 3 proteolytic activity as determined by an in vitro assay. Neuromuscul Disord 2007; 17(2):148–156.PubMedCrossRefGoogle Scholar
  64. 64.
    Krahn MBR, Pecheux C, Hammouda EH et al. Screening of the CAPN3 gene in patients with possible LGMD2A. Clin Genet 2006; 69(5):444–449.PubMedCrossRefGoogle Scholar
  65. 65.
    Ono Y, Shimada H, Sorimachi H et al. Functional defects of a muscle-specific calpain, p94, caused by mutations associated with limb-girdle muscular dystrophy type 2A. J Biol Chem 1998;273:17073–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Duguez S, Bartoli M, Richard I. Calpain 3: A key regulator of the sarcomere? FEBS J 2006; 273(15)3427–3436.PubMedCrossRefGoogle Scholar
  67. 67.
    Cohen N, Kudryashova E, Kramerova I et al. Identification of putative in vivo substrates of calpain 3 by comparative proteomics of overexpressing transgenic and nontransgenic mice. Proteomics 2006; 6(22):6075–6084.PubMedCrossRefGoogle Scholar
  68. 68.
    Richard I, Roudaut C, Marchand S et al. Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated IkappaBalpha/nuclear factor kappaB pathway perturbation in mice. J Cell Biol 2000; 151(7):1583–1590.PubMedCrossRefGoogle Scholar
  69. 69.
    Udd B and Griggs R. Distal myopathies. In: AG Engel, C Franzini-Armstrong (eds.) Myology 3rd edition. New York: McGraw-Hill, 2004; 1169–1185.Google Scholar
  70. 70.
    Pinotsis N, Petoukhov M, Lange S et al. Evidence for a dimeric assembly of two titin/telethonin complexes induced by the telethonin C-terminus. J Struct Biol 2006; 155(2):239–250.PubMedCrossRefGoogle Scholar
  71. 71.
    Matsumoto Y, Hayashi T, Inagaki N et al. Functional analysis of titin/connectin N2-B mutations found in cardiomyopathy. J Muscle Res Cell Motil 2005; 26(6–8):367–374.PubMedGoogle Scholar
  72. 72.
    Bos JM, Poley RN, Ny M et al. Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein and telethonin. Mol Genet Metab 2006; 88(1):78–85.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2008

Authors and Affiliations

  • Bjarne Udd
    • 1
    • 2
    • 3
  1. 1.Department of NeurologyTampere University Hospital and Medical SchoolTampereFinland
  2. 2.Folkhälsan Institute of Genetics, Biomedicum, C304University of HelsinkiHelsinki
  3. 3.Department of NeurologyVasa Central HospitalVasaFinland

Personalised recommendations